Holen Sie sich die Stockscreener-App
45.81
3.67%
1.62
Veracyte Inc Aktie (VCYT) Neueste Nachrichten
Neogen Stock Rallies 83% YTD: What's Driving the Surge? - Zacks Investment Research
Veracyte, Inc. (VCYT) Stock Forecasts - Yahoo Finance
ETFs Investing in Veracyte, Inc. Stocks - TradingView
Preferred dividends of Veracyte, Inc. – HAN:12V - TradingView
Veracyte, Inc. Cash Flow – HAN:12V - TradingView
Veracyte, Staar Surgical, Corning - TradingView
Veracyte’s Decipher test shows predictive value in prostate cancer - Investing.com
Phase III Trial Demonstrates Veracyte’s Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation - marketscreener.com
For 44% with low scores, added hormone therapy showed no statistically significant benefit against 10-year cancer spread. - Stock Titan
Veracyte Inc. R (12V.MU) Q1 FY2026 earnings call transcript - Yahoo Finance
Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026 - The Manila Times
Eight studies will examine who with prostate cancer may benefit from more treatment - Stock Titan
Veracyte (VCYT) Surges 10.8%: Is This an Indication of Further Gains? - Yahoo Finance
Form 144 VERACYTE For: 25 September By Investing.com - Investing.com South Africa
Form 144 VERACYTE For: 25 September - Investing.com India
Veracyte stock rises 10.77 percent toward its yearly high - AD HOC NEWS
Here's How Much a $1000 Investment in Veracyte Made 10 Years Ago Would Be Worth Today - Eastern Progress
Is Veracyte Inc (VCYT) Overvalued After 10.8% Rally? GF Value Sa - GuruFocus
A Veracyte (VCYT) director plans a $352,500 share sale after selling 5,000 shares. - Stock Titan
Veracyte Insiders Sold US$1.3m Of Shares Suggesting Hesitancy - Moomoo
Understanding Momentum Shifts in (VCYT) - Stock Traders Daily
Veracyte global chief commercial off. John Leite sells $160,600 stock By Investing.com - Investing.com Canada
Form 4 Veracyte Inc For: 23 September - Investing.com India
Insider Sell: Global Chief Commercial Officer John Leite Sells 4 - GuruFocus
Veracyte global chief commercial off. John Leite sells $160,600 stock - Investing.com
Form 4 Veracyte Inc For: 23 September By Investing.com - Investing.com Australia
Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets - Benzinga
A Look at Veracyte Inc (VCYT) After 4.4% Gain -- GF Value $39.14 vs Price $41.52 - GuruFocus
Veracyte (NASDAQ: VCYT) officer to sell 4,015 shares under Rule 144 - Stock Titan
Veracyte (NASDAQ:VCYT) Offers Affordable Growth Backed by Strong Health and Cash Flow - ChartMill
Piper Sandler Maintains Veracyte(VCYT.US) With Buy Rating, Maintains Target Price $54 - Moomoo
Veracyte Inc. (NASDAQ: VCYT) Director Holstein Jens Disposes 5,000 Shares at $40.95 Each - Kalkine Media
Veracyte (VCYT) Dropped, But What Is Driving Attention Now? - simplywall.st
Director Jens Holstein Sells 5,000 Shares of Veracyte (VCYT) - GuruFocus
A Look at Veracyte Inc (VCYT) After 4.1% Decline -- GF Value $39 - GuruFocus
Veracyte Director Jens Holstein Executes Sale of 5,000 Shares Under 10b5-1 Plan - Kalkine Media
Veracyte (VCYT) director offloads 5,000 shares under plan - Stock Titan
Craig-Hallum Maintains Veracyte(VCYT.US) With Buy Rating - Moomoo
Veracyte Adds Another Stream to Bladder Franchise, UBS Says - marketscreener.com
Veracyte at Morgan Stanley conference: growth, deals and new tests By Investing.com - Investing.com Nigeria
Veracyte at Morgan Stanley conference: growth, deals and new tests - Investing.com
Needham reiterates Veracyte stock rating at Buy on genomics deal By Investing.com - Investing.com Nigeria
Needham Maintains Veracyte(VCYT.US) With Buy Rating, Maintains Target Price $69 - Moomoo
Needham reiterates Veracyte stock rating at Buy on genomics deal - Investing.com
Veracyte acquires Convergent Genomics for up to $180 million By Investing.com - Investing.com Australia
VCYT Looks 5.7% Overvalued on GF Value™ as Insider Selling Persi - GuruFocus
VCYT Looks 5.7% Overvalued on GF Value™ After Convergent Genomics Acquisition - GuruFocus
Veracyte acquires Convergent Genomics for up to $180 million - Investing.com
Veracyte Buys Convergent Genomics - marketscreener.com
0.97%
0.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):